Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, but in average-risk populations,
Rearrangements of the anaplastic lymphoma kinase (ALK) gene occur infrequently in non-small-cell lung cancer (NSCLC), but provide an important paradigm for oncogene-directed therapy in this disease. Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in
Reductions in breast cancer risk for women with a hysterectomy receiving oestrogen-alone therapy have persisted since termination of active treatment on the Women's Health Initiative trial. The few deaths among women diagnosed with breast cancer during this trial limit the interpretation of the reduced mortality for women receiving oestrogen alone compared with placebo.
